CD8A and neoplasm: Further in vivo studies demonstrated that the pCSP vaccine significantly inhibited tumor growth in Panc02 tumor-bearing mice, increased the proportion of CD8+ T cells in the spleen, and boosted the secretion of IFN-γ, while also enhancing the immune activity of effector T cells in the tumor microenvironment.